T. Rowe Price Investment Management, Inc. Immatics N.V. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immatics N.V. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 10,604,777 shares of IMTX stock, worth $56.2 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
10,604,777
Previous 7,379,636
43.7%
Holding current value
$56.2 Million
Previous $84.2 Million
10.45%
% of portfolio
0.05%
Previous 0.05%
Shares
7 transactions
Others Institutions Holding IMTX
# of Institutions
93Shares Held
92.5MCall Options Held
313KPut Options Held
377K-
Wellington Management Group LLP Boston, MA10.4MShares$55.2 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$49.7 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$38.6 Million0.57% of portfolio
-
Rtw Investments, LP New York, NY6.54MShares$34.7 Million0.76% of portfolio
-
Vestal Point Capital, LP New York, NY6.28MShares$33.3 Million2.65% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $404M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...